11/6/2026

speaker
Conference Operator
Webcast Operator

Greetings and welcome to the VaxArt third quarter 2026 Stockholder Fireside Chat. A question and answer session will follow management's opening remarks. Individual investors may submit written questions via the webcast portal at any time during the presentation. As a reminder, this conference is being recorded. I would now like to turn the webcast over to David Carey of FinPartners.

speaker
David Carey
FinPartners Representative

Good afternoon and welcome to today's call. Joining us from VaxArt are Steven Lo, Chief Executive Officer, Mark Watson, Lead Independent Director and member of the Board's Stockholder Engagement Committee, Dr. Rocky Bono, Independent Director and Chair of the Stockholder Engagement Committee, Dr. Sean Tucker, Founder and Chief Scientific Officer, Dr. James F. Cummings, Chief Medical Officer, and Jeroen Grasman, Chief Financial Officer. Before we begin, I would like to remind everyone that during the conference call, Backstart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations, any partnerships with third parties, timing of any anticipated regulatory milestones or clinical data readouts, the company's future cash runway, ability to raise capital, and its product development progress. Actual results could materially differ from those discussed in these forward-looking statements due to a number of important factors, including the uncertainty inherent in clinical development and regulatory processes and other risks described in the risk factors section of VaxArt's most recently filed end report on Form 10-K and periodic reports filed with the SEC. VaxArt takes no obligation to update any forward-looking statements after the date of this call. I'll now turn the call over to Steve Lowe.

speaker
Steven Lo
Chief Executive Officer

Thanks, David. Good afternoon, everyone, and thank you for joining us today for our third quarter 2026 Fireside Chat, the fifth quarterly Fireside Chat and sixth overall Fireside Chat we've hosted. These discussions are an important part of our ongoing commitment to maintaining transparency and visibility for our stockholders. The third quarter and recent weeks have been a productive period for VaxArt across our clinical programs, pipeline validation, and corporate governance. Our primary operational focus remains executing the main cohort of our Phase 2B COVID-19 trial. Following the encouraging 12-month head-to-head safety data we reported in July from our 400-participant Sentinel cohort, Our clinical operations and trial site teams have been actively advancing the approximately 5,000 participant main cohort. We expect to report efficacy and safety data by mid-year 2027. In addition to our clinical momentum, we have taken important steps to strengthen our board leadership and corporate oversight. To speak more about our governance initiatives and introduce our newest director, I'd like to turn the call over to our lead independent director, Mark Watson. Mark?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API